An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Key facts
- Where
- Beijing, Chengdu, Guangzhou, Jiangxi, Jilin City, Shenyang, Wuhan, Xi’an és Zhengzhou, KínaSee the 12 sites
- Phase
- 3. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in Kína
- Beijing Anzhen HospitalBeijing, KínaNo longer taking part
- Beijing Chao-Yang Hospital, Capital Medical UniversityBeijing, KínaNo longer taking part
- Fuwai Hospital ，CAMS&PUMCBeijing, KínaNo longer taking part
- Peking University Third HospitalBeijing, KínaNo longer taking part
- Sichuan Provincial People's HospitalChengdu, KínaNo longer taking part
- Nanfang HospitalGuangzhou, KínaNo longer taking part
- The Second Affiliated Hospital of Nanchang UniversityJiangxi, KínaNo longer taking part
- The First Hospital of Jilin UniversityJilin City, KínaNo longer taking part
- Shengjing Hospital Of China Medical UniversityShenyang, KínaNo longer taking part
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhan, KínaNo longer taking part
- The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, KínaNo longer taking part
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, KínaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Corxel Pharmaceuticals
- Trial code
- NCT06116968
- Record updated
- 2026. január 21.
- Original description
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.Read full original descriptionShow less
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.
Inclusion: Completion of a Cytokinetics trial investigating CK-3773274; LVEF ≥55% at the Screening Visit.
Exclusion: Has participated in another investigational device or drug study or received an investigational device or drug <1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted; Since completion of a previous study of aficamten has:Developed new-onset paroxysmal or permanent atrial fibrillation (AF) requiring rhythm restoring treatment (e.g., direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) <30 days prior to screening. Patient may rescreen for JX01003 after 30 days if heart rate (HR) <100 bpm and/or rhythm is stable >30 days; Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation); History of appropriate implantable cardioverter defibrillator (ICD) shock within 30 days prior to screening; Has received treatment with mavacamten; Had a confirmed LVEF <40% with an associated dose interruption during participation in a prior study with aficamten.